NEW YORK, Nov 6 (Reuters) - Novo Nordisk CEO

Mike Doustdar said during a White House event on Thursday that

the company's bid for obesity biotech Metsera is higher than the

one from rival Pfizer Inc. ( PFE ), which has sued both Metsera

and Novo over the terms of their rival deal.

"As of today, our bid is higher, and our message to Pfizer ( PFE )

is that if they would like to buy the company, then put your

hand in the pocket and bid higher," Doustdar said.